Drug Type Monoclonal antibody |
Synonyms 卫拓 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | China | 18 May 2022 | |
Esophageal Carcinoma | Phase 1 | China | 18 May 2022 | |
Stomach Cancer | Phase 1 | China | 18 May 2022 |